Internal Medicine, Endocrinology, Diabetes, & Metabolism · Shelbyville, IN
NPI
1043354483
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
4
Medicare group memberships
Hospitals
4
Hospital affiliations
30 W Rampart St Ste 230
Shelbyville, IN, 46176
Phone (317) 398-7644
Groups this clinician bills Medicare through
Medicare paid, 2024
$225K
52,354 services
Medicare patients, 2024
233
Average age 71
Drug cost, 2024
$3.0M
5,129 prescriptions
Company payments, 2025
$135
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kerri A Kissell was code J7336 (capsaicin 8% patch, per square centimeter), 46,481 times for 15 patients. In total Kerri A Kissell billed 52,354 services in 27 codes, and Medicare paid $225K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J7336 Capsaicin 8% patch, per square centimeter | Office | 46,481 | 15 | $2.55 | $119K |
| J0897 Injection, denosumab, 1 mg | Office | 1,200 | 13 | $20.49 | $25K |
| 99214 Office E&M - Established | Office | 258 | 157 | $79.85 | $21K |
| 83037 Blood Count | Office | 221 | 134 | $9.39 | $2,076 |
| 95251 Test - Miscellaneous | Office | 112 | 64 | $24.48 | $2,741 |
| 99215 Office E&M - Established | Office | 64 | 50 | $119.54 | $7,651 |
| 64632 Musculoskeletal | Office | 45 | 16 | $95.47 | $4,296 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 39 | 33 | $12.23 | $477 |
| 96372 Injection Administration | Office | 38 | 16 | $10.54 | $401 |
| 99204 Office E&M - New | Office | 27 | 27 | $104.77 | $2,829 |
| 95250 Test - Miscellaneous | Office | 22 | 20 | $101.55 | $2,234 |
| 99205 Office E&M - New | Office | 21 | 21 | $141.48 | $2,971 |
By year: 2022 $76K for 6,980 services; 2023 $130K for 23,176 services; 2024 $225K for 52,354 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83037 Blood Count | 221 | 134 | $9.39 | $2,076 |
Medicare prescription drug claims, 2024
In 2024, the drug Kerri A Kissell prescribed most often to Medicare patients was Levothyroxine Sodium, with 611 prescriptions and refills. In total Kerri A Kissell wrote 5,129 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 611 | 1,396 | 139 | $5,320 |
| Mounjaro Tirzepatide | 475 | 590 | 95 | $624K |
| Farxiga Dapagliflozin Propanediol | 413 | 776 | 102 | $436K |
| Ozempic Semaglutide | 354 | 520 | 98 | $486K |
| Metformin Hcl Generic | 226 | 566 | 80 | $1,661 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 194 | 392 | 62 | $26K |
| Jardiance Empagliflozin | 171 | 327 | 41 | $186K |
| Methimazole Generic | 158 | 339 | 35 | $1,021 |
| Atorvastatin Calcium Generic | 106 | 261 | 29 | $939 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 99 | 146 | 24 | $95K |
| Alendronate Sodium Generic | 96 | 234 | 34 | $666 |
| Rybelsus Semaglutide | 80 | 118 | 22 | $111K |
| Januvia Sitagliptin Phosphate | 79 | 133 | 23 | $71K |
| Rosuvastatin Calcium Generic | 77 | 157 | 20 | $797 |
| Synthroid Levothyroxine Sodium | 72 | 149 | 15 | $5,079 |
Brand drugs: 2,896 claims; generic drugs: 1,855 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kerri A Kissell $135 ($135 in general payments such as food, travel and fees) from 3 companies. The largest payer was Novo Nordisk Inc with $96.81.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.